Journal of Oncology

Review Article

DNA Repair Deficiency in Breast Cancer: Opportunities for Immunotherapy

Table 2

Current and completed clinical trials of immune checkpoint inhibition in breast cancer.


Immunotherapy	Subtype	Target	Combination	Study	Phase

Pembrolizumab	TNBC ER+/HER2-	PD-1	Single agent	NCT02555657 KEYNOTE-119 [62]	3

Pembrolizumab	BRCA mutated	PD-1	Single Agent	NCT03025035	2

Pembrolizumab	TNBC ER+/HER2-	PD-1	Single agent	NCT02447003 KEYNOTE-086 [63]	2

Pembrolizumab	TNBC ER+/HER2-	PD-1	Single agent	NCT01848834 KEYNOTE-012 [64]	1B

Pembrolizumab	TNBC ER+/HER2-	PD-1	Single agent	NCT02054806 KEYNOTE-028 [65]	1

Pembrolizumab	ER/PR-	PD-1	Single Agent	NCT03197389	1

Pembrolizumab	TNBC and HR+HER2-	PD-1	Decitabine + Soc NACT	NCT02957968	2

Pembrolizumab	TNBC	PD-1	EDP1503	NCT03775850	2

Pembrolizumab	TNBC	PD-1	Imprime PGG	NCT02981303	2

Pembrolizumab	HR+HER2-	PD-1	Eribulin	NCT03222856 KELLY [66]	2

Pembrolizumab	TNBC	PD-1	Chemotherapy	NCT01042379 I-SPY 2 [64, 67]	2

Pembrolizumab	TNBC	PD-1	Galinpepimut-S	NCT03761914	2

Pembrolizumab	TNBC	PD-1	Nab-paclitaxel + Epirubicin + Cyclophosphamide	NCT03289819	2

Pembrolizumab	TNBC	PD-1	Chemotherapy	NCT02622074 KEYNOTE-173 [68]	1B

Pembrolizumab	ER+HER2- / TNBC	PD-1	Radiation Radiation	NCT03366844	1

Pembrolizumab	Metastatic BC	PD-1	High Intensity Ultrasound	NCT03237572	1

Pembrolizumab	All	PD-1	Stereotactic Ablative Radiosurgery	NCT02303366 BOSTON II	1

Pembrolizumab	TNBC	PD-1	PVX-410 vaccine	NCT03362060	1

PDR001	TNBC	PD-1	Canakinumab CJM112 Trametinib EGF816	NCT02900664	1B

PDR001	TNBC	PD-1	LCL161 Everolimus Panobinostat QBM076	NCT02890069	1

PDR001	TNBC	PD-1	NZV930 NZV930 + NIR178	NCT03549000	1

Durvalumab	TNBC	PD-L1	Single agent Taxane-anthracycline chemotherapy	NCT02685059 GeparNuevo [69]	2

Durvalumab +/- Tremelimumab	All	PD-L1 +/- CTLA-4	Poly ICLC	NCT02643303	2

Durvalumab	BRCA mutated HER2-	PD-L1	Olaparib +Bevacizumab	NCT02734004 MEDIOLA [70]	2

Durvalumab	TNBC	PD-L1	Paclitaxel and Carboplatin	NCT03616886 SYNERGY	2

Durvalumab	BRCA mutated HER2-	PD-L1	Olaparib	NCT02734004 MEDIOLA [70]	1

Durvalumab	TNBC	PD-L1	Paclitaxel, Carboplatin and Oleclumab	NCT03616886 SYNERGY	1

Durvalumab	TNBC	PD-L1	Cediranib Olaparib Cediranib + Olaparib	NCT02484404	1

Atezolizumab	TNBC	PD-L1	Single agent	NCT01375842 [71]	1

Atezolizumab	TNBC	PD-L1	Nab-paclitaxel	NCT02425891 IMpassion130 [14]	3

Atezolizumab	HER2+	PD-L1	Trastuzumab Emtansine	NCT02924883 KATE2 [72]	2

Atezolizumab	TNBC	PD-L1	Cabozantinib	NCT03170960	1B

Atezolizumab	TNBC	PD-L1	RO7198457	NCT03289962	1

Nivolumab	TNBC	PD-L1	Romidepsin + Cisplatin	NCT02393794	2

Nivolumab	TNBC	PD-L1	Capecitabine	NCT03487666 OXEL [73]	2

Nivolumab	Metastatic	PD-L1	Nab-paclitaxel	NCT02309177	1

Nivolumab	All	PD-L1	COM701	NCT03667716	1

Avelumab	TNBC	PD-L1	Additional	NCT02926196 A-Brave [74]	3

Avelumab	TNBC	PD-L1	Utomilumab	NCT02554812 JAVELIN [75]	2

Avelumab	All	PD-L1	Utomilumab +/- Radiation Utomilumab + PF-04518600 PF-04518600 +/- Radiation Utomilumab + PF-04518600 + Radiation Cisplatin + Radiation	NCT03217747	2

FAZ053	TNBC	PD-L1	Single Agent PDR001	NCT02936102	1

LY3300054	HR+HER2-	PD-L1	Single Agent Ramucirumab Abemaciclib Merestinib LY3321367	NCT02791334	1

Tremelimumab	TNBC	CTLA-4	Monotherapy	NCT02527434 [76]	2

MSB0011359C	ER+ and/or PR+, HER2-	PD-L1 and TGF-β	Radiation	NCT03524170 RACHEL 1	1

LAG525	TNBC	LAG3	Single agent PDR001 / Carboplatin or combination	NCT03499899	2

Toripalimab	TNBC	PD-1	Single Agent	NCT02838823	1

TT1-621	All	CD47	Single Agent +PD1/PDL1 inhibitor +Pegylated interferon- α2a +T-Vec +Radiation	NCT02890368	1

Ipilimumab + Nivolumab	HER2-	CTLA-4 PD-1	Bicalutamide	NCT03650894	2

Ipilimumab + Nivolumab	HER2-	CTLA-4 PD-1	__	NCT03789110 NIMBUS	2

Epacadostat + Pembrolizumab	All	IDO-1 PD-1	INCAGN01876 (anti-GITR)	NCT03277352	1/2

Ipilimumab + Nivolumab	All	PD-1 PD-L1	Entinostat	NCT02453620	1

Nivolumab + Pembrolizumab + Atezolizumab	HER2+	PD-L1 PD-1 PD-L1	FT500 (Natural Killer cell)	NCT03841110	1

Ipilimumab + Nivolumab	All	CTLA-4 + PD-L1	Cryoablation	NCT02833233 [77]	N/A